Roche: positive data in inflammatory bowel disease.

(CercleFinance.com) - Roche said on Tuesday that new data suggests that an investigational antibody can provide meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease.


Data from a phase III study evaluating the safety and efficacy of etrolizumab versus placebo in previously treated patients with moderate-to-severe Crohn's disease suggest an early and persistent symptomatic remission, the Swiss firm said.

The program is supposed to enrol over 3,400 patients across eight pivotal phase III studies, for ulcerative colitis and Crohn's disease.

The findings were presented at the United European Gastroenterology Week (UEGW) congress, that is currently taking place in Barcelona.


Copyright (c) 2017 CercleFinance.com. All rights reserved.